Intellia Therapeutics Announces Third Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Intellia Therapeutics (NTLA) Tops Q3 EPS by 13c, Revenues Beat
October 31, 2019 7:46 AM EDTIntellia Therapeutics (NASDAQ: NTLA) reported Q3 EPS of ($0.49), $0.13 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $10.62 million versus the consensus estimate of $9.43 million.
On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosisExpects to nominate its first T cell receptor-directed engineered cell therapy development candidate for the treatment of acute myeloid leukemia by the end of 2019Presented preclinical data including... More